1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Malignant Glioma Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H1 2018

Malignant Glioma Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H1 2018

  • February 2018
  • 205 pages
  • ID: 5308569

Summary

Table of Contents

Search Inside

Glioma clinical trials report from VPA Research provides comprehensive analysis and trends in global Glioma disease clinical trials. The research work analyzes the evolution of Glioma clinical trial trends across countries and regions.

The report focuses on drugs and therapies being evaluated for Glioma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Glioma clinical trials.

Major drugs under development in Glioma are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.

Scope of the Report-
- Number of Glioma clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
- Trial information by Phase and Subjects recruited
- Trial information by status, type, sponsor type
- Drugs used for treatment of Glioma
- Both observational and interventional trials analyzed
- Success rates of trials are analyzed
- Trends in enrollment over the past ten years identified
- Leading sponsors of Glioma clinical trials worldwide are listed

Reasons to Buy-
- Track competition and design competitive advantages
- Identify right partners to associate with for further research
- Evaluate potential opportunities available in further clinical trials of the disease
- Formulate business development strategies through success rates of clinical trials
- Identify quick markets for recruiting subjects based on trials count by each market

Glioma- The condition occurs when the glial cells in the brain are affected and account for around one-third of all brain tumors. On the basis of location, these are classified as supratentorial (above tentorium) and infratentorial (below tenotrium).

On the basis of pace of development, these are categorized as Low grade (grades 1 and 2) and high grade (3 and 4). Treatment options vary with the grade of the disease, but most often it includes a combination of medicine, surgery, radiation and chemo therapies.

Malignant Glioma- Malignant Glioma is the most regular subtypes of glioma condition occurring in patients aged between 60 and 80. The condition is classified as grade 3 and grade 4, which comprises anaplastic high-grade gliomas and glioblastomas respectively.

High Grade Glioma- Malignant or high-grade glioma tumors are categorized as Grade 3 and Grade 4. Of this Grade 3 tumor types include-
Anaplastic astrocytoma- The rare disease type comprises an estimated one-third of all astrocytoma types. Often observed in older persons, the condition can occur in any aged person. Astrocytoma emerges from star shaped cells in the brain, called astrocytes.

Anaplastic oligodendroglioma- It is a rare type of malignant tumor occurring mainly between 45 and 50 years of age. They possess abnormal genetic material and unique molecular, clinical, and histological characteristics and are important to diagnose.

Anaplastic oligoastrocytoma- Oligoastrocytoma occurs when either oligodendrocytes and astrocytes or both grow rapidly, causing formation of tumors in the brain. The term ‘Anaplastic’ refers to condition when tumor can spread into nearby tissues. They occur in Cerebrum area.

Anaplastic ependymoma- The fast growing subtype occurs primarily in posterior fossa part. The tumor cells show rapid growth pace and are associated with a less favorable prognosis and have higher possibility to infiltrate around the brain or disseminate into cerebrospinal fluid resulting in drop metastases.

Glioblastoma- The grade 4 type condition is further classified as primary and secondary types. The primary subtype occurs without earlier diagnosis of low grade tumors while the secondary type arouses from development of grade 2 or 3 subtypes. Tumor occurs as a result of accumulation of different mutations.

Pontine Gliomas- Diffuse intrinsic pontine glioma (DIPG) is an aggressive type of malignant glioma, arising from glioma tissue. As these are observed in the bottom area of the brain, they are tough to be treated. It is observed mostly in children.

Low Grade Glioma (LGGs) or often referred to as Grade-1 and 2 tumors, arouse from brain cells including astrocytes and oligodendrocytes. Causing mild and large seizures, the Glioma type is treated through a combination of surgery, chemotherapy, and radiation on the basis of disease condition. The condition is primarily observed in young and healthy individuals. Compared to high grade Glioma, these patients survive for long periods and lead quality life as this is a slow growth disease.

On the basis of appearance under microscope and genetic modifications, Low grade gliomas are classified as-
Pilocytic astrocytomas — Observed in adults aging less than 25 and progresses very slowly compared to other types

Diffuse astrocytomas — Most observed subtype of low-grade glioma. Late 30’s individuals are the most affected age. Type of modification in IDH isocitrate-dehydrogenase gene determines the sub-types of Diffuse astrocytomas.

Oligodendrogliomas — Slow growing tumors, having mutation in the IDH gene in terms of missing 1p and 19q chromosomes.

Gangliogliomas — Posesses both gliomas and tumor related characteristics

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Clinical Research in Squamous Cell Carcinoma in H2, 2018

Clinical Research in Squamous Cell Carcinoma in H2, 2018

  • $ 2500
  • August 2018

Squamous Cell Carcinoma Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Squamous Cell Carcinoma Global Clinical Trials Review, H2, 2018" provides an overview of Squamous ...

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2018

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2018

  • $ 3500
  • August 2018

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2018SummaryCarcinoembryonic Antigen Related ...

Clinical Research in Granulomatosis with Polyangiitis (Wegener's Granulomatosis) in H2, 2018

Clinical Research in Granulomatosis with Polyangiitis (Wegener's Granulomatosis) in H2, 2018

  • $ 2500
  • September 2018

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) ...


ref:plp2018

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on